Aehr Test Systems: Time For A Breather (Rating Downgrade) (NASDAQ:AEHR)

In May here I wrote about the unique technical and fundamental setup for Aehr Test Systems (NASDAQ:AEHR) at $32 a share. I suggested a low-volume gain in shares following a few months of selling, combined with a high short interest position betting against future success, could generate above-average gains over the summer (assuming solid underlying business growth would continue). And, when the company reported strong fundamental growth, short covering did take place, creating a rapid +50% gain in the share quote.

Several readers have asked me if my view has changed in recent weeks. My answer is Yes. Expecting another period of consolidation, perhaps until the end of the year, makes sense today. Does that mean the company is an outright Sell? Not necessarily, but traders and even many long-term investors may want to liquidate part of their position or hedge it through either covered calls or selective put option buying.

The main reason for my change of heart is the valuation has reached for a higher height, while the global economy’s “prospects” have turned down a little since May. In my opinion, growth stocks should now be avoided, as long-term interest rates moving higher this summer will eventually cause a weaker economy and a knockdown in pricing for equities on the “expensive” side of the ledger, like Aehr. (I have written a number of bearish articles on Big Tech names for example over the summer months.)

Valuation Getting Stretched

The way Seeking Alpha counts things, the relative valuation of Aehr vs. peers and competitors in testing equipment and semiconductors has moved from a Grade of “C” in May to an “F” in September. Why?

The majority of individual companies have traded flat to lower in price vs. the large uptick in Aehr is one reason. Another is the rise in long-term interest rates of 0.5% to 1% since May has taken a leg out of the valuation support for the stock. Right now, analysts are projecting an earnings yield of 2% for fiscal year 2024 (ending next May), roughly 3% for FY 2025, and closer to 4% for FY 2026, on a $50 stock quote.

Sure, the growth rates are phenomenal at Aehr. However, I can lock in risk-free Treasury yields well above 4% into the middle of 2026. The guaranteed 4.5% to 5.5% annual yield from bonds, on top of the guaranteed 100% return of my upfront investment appears to be a far smarter place to park capital, especially if a recession is approaching into calendar 2024.

Back in May, similar Aehr earnings yield calculations were nearer Treasury rates, translating into investors receiving a decent business return on investment in addition to the promise/hope of outsized business growth delivering HIGHER operating yields than Treasury rates three years from now. So, the investment equation has changed, arguing against ownership.

Technical Momentum Picture

The momentum chart readout has remained somewhat bullish in my research, looking at daily formula-based sorts on thousands of equities. If my only data on the company to make a decision was centered around technical analysis, Aehr would be closer to a Buy rating.

That’s not to say some technical issues of weakening momentum do not exist. Below I have drawn a 12-month chart of daily price and volume changes. The first point to highlight is the low 21-day Average Directional Index of May (circled in green) jumped to the highest reading of the year in early August (circled in red). I much prefer buying stocks with low-volatility ADX scores, before a big upswing in price.

Second, the 14-day Ease of Movement indicator highlighted an unusual lack of buyers later in August (purple arrow). Basically, it didn’t take much volume selling to drive the stock quote down by almost -25% over three weeks. In a perfect world of technical trading, EMV should be quite positive as price rises.

Third, Negative Volume Index scores have been sliding since January (blue arrow). As opposed to regular buying trends on slower-news days (which I prefer), weaker-volume sessions have witnessed a greater number of sellers than buyers, on average. NVI zigzags are something to worry about, although not necessarily a deal breaker for bulls historically.

Final Thoughts

Is now the time to dump all of your Aehr shares? Probably not. Seeking Alpha’s computerized sorting system still gives the stock a Top 20% rank out of 4,661 equities.

Yet, I do feel now is the time to hedge gains or lighten up your position. If you do not want to sell your shares, one successful strategy may be to sell covered calls a few months out for an expiration, near the money for a strike price.

At the very least, I would wait for lower pricing to initiate buy order. I am projecting a $40 price as an area having slightly better valuation statistics to support owning the company again. And, a drop to $35 is not out of the question if a recession appears into early 2024.

Nevertheless, for upside surprises, I can envision strong operating results holding the share quote in the $45 to $50 range into January. The company’s focus on building new testing equipment for silicon carbide-based and other power semiconductors sold to the rapidly expanding electric vehicle [EV] industry could support higher quotes again during 2024.

I personally sold my Aehr position for a nice gain, buying in the low-$30s and liquidating in the low-$40s months later. (I like to take quick gains in non-taxable brokerage accounts, for compounding reasons.)

Weighing all the pros and cons for this investment name, I am downgrading my rating from Buy in May to Hold/Neutral in September.

Thanks for reading. Please consider this article a first step in your due diligence process. Consulting with a registered and experienced investment advisor is recommended before making any trade.